4^th February marks World Cancer Day 2021, this global initiative is led by the Union for International Cancer Control (UICC) is dedicated to raising awareness and improving education surrounding cancer and ensuring treatment is globally available.

Biorex Diagnostics are proud to continue their commitment to investing in extensive research and development in a range of diagnostic cancer tests. Each year, Biorex Diagnostics invest 30% of annual turnover towards the research & development of custom tests including early cancer detection.  The tests will assist clinicians to identify the presence of cancer on average four years before standard clinical diagnosis. Unlike the tumour antigens themselves, the levels of autoantibodies can be high even in the presence of an early stage tumour, due to the signal magnification created by the body’s immune response to a cancer. These autoantibodies can be measured easily on a simple enzyme-linked immunosorbent assay (ELISA) platform of which Biorex Diagnostics is making readily available in clinical laboratories around the world.

Our expert R&D team work collaboratively with many universities and research institutions including Queen’s University Belfast, the University of Cape Town and the University of Nottingham to develop custom tests, making new ideas a viable entity by utilising in-house resources at our UK-based ISO 13485:2016-accredited facility.

For more information email info@biorexdiagnostics.com